Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults

The development of long-acting growth hormone secretagogues that can sustain physiological growth hormone elevation represents a major advance over short-acting alternatives. This clinical study by Teichman, Neale, Lawrence, and colleagues evaluated CJC-1295's ability to produce prolonged stimulation of growth hormone and insulin-like growth factor I (IGF-1) in healthy adults.

The researchers administered CJC-1295, a long-acting analog of growth hormone-releasing hormone, to healthy adult volunteers and measured growth hormone and IGF-1 levels over an extended period. This human clinical study provided direct evidence of the peptide's pharmacokinetic and pharmacodynamic properties in the target population.

The results demonstrated that CJC-1295 produces prolonged elevation of both growth hormone and IGF-1 levels in healthy adults. The sustained activity profile confirmed CJC-1295's effectiveness as a long-acting growth hormone secretagogue, with the potential for less frequent dosing compared to shorter-acting alternatives.

This clinical study in healthy adults provides foundational evidence for CJC-1295's therapeutic utility. The confirmed prolonged activity profile supports its use in protocols requiring sustained growth hormone elevation, with implications for body composition optimization, recovery support, and age-related growth hormone decline.